Orion Oyj (ORIN.F) Stock Overview
Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
ORIN.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Orion Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €78.95 |
| 52 Week High | €81.30 |
| 52 Week Low | €78.95 |
| Beta | 0.36 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 69.73% |
| 5 Year Change | 94.80% |
| Change since IPO | 218.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORIN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | -1.0% |
| 1Y | n/a | 21.3% | 19.4% |
Return vs Industry: Insufficient data to determine how ORIN.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ORIN.F performed against the US Market.
Price Volatility
| ORIN.F volatility | |
|---|---|
| ORIN.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ORIN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ORIN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 4,029 | Liisa Hurme | www.orionpharma.com |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
| ORIN.F fundamental statistics | |
|---|---|
| Market cap | US$11.41b |
| Earnings (TTM) | US$577.11m |
| Revenue (TTM) | US$2.18b |
Is ORIN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORIN.F income statement (TTM) | |
|---|---|
| Revenue | €1.89b |
| Cost of Revenue | €676.50m |
| Gross Profit | €1.21b |
| Other Expenses | €712.70m |
| Earnings | €500.30m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | 3.56 |
| Gross Margin | 64.20% |
| Net Profit Margin | 26.48% |
| Debt/Equity Ratio | 22.6% |
How did ORIN.F perform over the long term?
See historical performance and comparisonDividends
Does ORIN.F pay a reliable dividends?
See ORIN.F dividend history and benchmarks| Orion Oyj dividend dates | |
|---|---|
| Ex Dividend Date | Mar 25 2026 |
| Dividend Pay Date | Apr 02 2026 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 14 days |
Does ORIN.F pay a reliable dividends?
See ORIN.F dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/18 17:30 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orion Oyj is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlie Haywood | BofA Global Research |
| Alexander Moore | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |